Arbutus Biopharma Corporation (ABUS)
Arbutus Biopharma Corporation (ABUS) is a healthcare company (biotechnology) based in the United States. The share price is $4.05, up 0.25% on the day, which values the company at $620.84M. Price as of 18 Nov 2026, 11:57 UTC, from Yahoo Finance.
Key facts
- Share price
- $4.05+0.25% today
- Market value
- $620.84M
- P/E ratio
- 3.6×last 12 months
- Funk Score
- 27/100
- Against its own history
- Well above its usual priceusual price $2.64
- 200-week average
- $3.4318% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Arbutus Biopharma Corporation in more detail
ABUS trades at 3.6× its last twelve months' earnings, -24.5× next year's expected earnings, 3.4× sales. Measured against its own history, the price is 54% above what its usual multiples would imply ($2.64) — well above its usual price. It sits 18% above its 200-week average of $3.43.
Over the last five fiscal years Arbutus Biopharma Corporation has compounded revenue 15.3% a year. Its Funk Score is 27 out of 100 (financial strength 3.8, profitability 2.5, growth 4.7, value 0.0, each out of 10).
In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Share count keeps rising.
Arbutus Biopharma Corporation (ABUS): questions and answers
What is ABUS's P/E ratio?
Arbutus Biopharma Corporation trades at 3.6× its last twelve months' earnings and -24.5× next year's expected earnings.
What is Arbutus Biopharma Corporation's market cap?
Arbutus Biopharma Corporation is valued at $620.84M at a share price of $4.05.
Is ABUS overvalued or undervalued?
Against its own history, ABUS is well above its usual price: the price is 54% above the $2.64 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is ABUS above its 200-week moving average?
Yes. ABUS is 18.0% above its 200-week average of $3.43. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Arbutus Biopharma Corporation growing?
Over the last five fiscal years Arbutus Biopharma Corporation's revenue grew 15.3% a year; over ten years revenue grew -4.9% a year.
Does ABUS pay a dividend?
Arbutus Biopharma Corporation does not currently pay a regular dividend.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Arbutus Biopharma Corporation (ABUS) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/ABUS
Underlying data: Yahoo Finance; company filings with the SEC.